The FDA found that the use of GLP-1s to treat diabetes and obesity do not cause suicidal thoughts or actions in a preliminary review of clinical trials and safety data reported to the agency.

The FDA has spent the past several months evaluating reports of suicidal thoughts and actions reported via the agency’s adverse event reporting system and determined that the reports did not indicate a clear connection to the drugs, underscoring that the data provided are limited and can be influenced by other factors. Similarly, the agency’s review of clinical trials of GLP-1s did not find a link between the drugs and suicidal thoughts and actions.

“However, because of the small number of suicidal thoughts or actions observed in both people using GLP-1 RAs and in the comparative control groups, we cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to look into this issue,” FDA wrote.

The FDA’s conclusion comes after an NIH-funded study published in Nature Medicine earlier this month found that semaglutide carried a lower risk of suicidal ideations compared to other non-GLP-1 obesity medications. A Novo Nordisk spokesperson told Endpoints News at the time that the company will continue to monitor reports of adverse reactions related to Ozempic and Wegovy, including suicidal ideation.

The FDA said it’s continuing to evaluate data further, including a meta-analysis of all clinical trials for GLP-1s and an analysis of post-marketing data in its Sentinel System, which collects large amounts of health data.

Leerink analysts noted that the FDA hasn’t given a timeline for when it will give another update. Meanwhile the European Medicines Agency’s safety committee is still reviewing the data around GLP-1s and the risk of suicidal thoughts and is slated to reconvene in April to discuss further.

The FDA underscores that patients should not stop taking GLP-1s before consulting their doctors and that healthcare professionals should continue monitoring and reporting instances of suicidal thoughts or actions associated with GLP-1s.

Source: https://endpts.com/fda-determines-glp-1s-not-linked-to-suicidal-thoughts-or-actions-in-preliminary-review/
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.

READ MORE

aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.

READ MORE